Generic Isentress (Raltegravir)

Isentress is Merck's brand of raltegravir, an HIV-1 integrase inhibitor taken as part of combination antiretroviral therapy to help manage long-term HIV infection. Generic raltegravir contains the same active ingredient at the same strengths and is prescribed for the same purpose, at a substantially lower cost. Used as prescribed by a licensed medical professional.

Raltegravir is an antiretroviral medicine belonging to the integrase strand transfer inhibitor (INSTI) class. Sold under the brand name Isentress by Merck, it is one component of a combination HIV treatment regimen and is never used on its own. Generic raltegravir supplied through licensed pharmaceutical manufacturers holds the identical active ingredient, strength and tablet form as the originator brand. It is intended to help control HIV-1 in adults and, in some regimens, children, always under the supervision of an HIV specialist.

HIV needs an enzyme called integrase to insert its genetic material into human immune cells. Raltegravir blocks this integrase step, interrupting how the virus copies itself and helping to lower the amount of HIV in the blood. It does not remove the virus from the body, which is why HIV is managed as a lifelong condition rather than cured. Taken consistently as part of combination therapy and monitored by a clinician, raltegravir supports viral suppression and helps protect immune function over time.

Raltegravir is prescribed for adults and, in certain regimens, children living with HIV-1 who require ongoing antiretroviral treatment. It is chosen by HIV specialists for its role within combination therapy and is often suited to people who need a well-tolerated integrase inhibitor or who have interactions with other drug classes. It is not a preventive medicine and is not used alone. Suitability, the right companion medicines and dosing are always decided by a clinician based on individual health, resistance testing and other treatments.

The usual adult dose of raltegravir is 400 mg twice daily, or 1200 mg once daily taken as two 600 mg tablets, always as part of combination antiretroviral therapy. Tablets can generally be taken with or without food, and the once-daily and twice-daily formulations are not interchangeable. Dosing for children, and any adjustment, is determined by the specialist. This is general information only; follow the exact dose, timing and regimen prescribed for you by a licensed medical professional and do not change it without advice.

Never change your dose on your own.

Commonly reported side effects of raltegravir can include headache, nausea, diarrhoea, tiredness and difficulty sleeping. Less commonly, changes in liver blood tests, rash or muscle-related symptoms may occur, and rare but serious skin or hypersensitivity reactions have been reported. Because raltegravir is taken with other antiretrovirals, some effects may relate to the wider regimen. This is not a complete list. Tell your clinician promptly about severe rash, muscle pain or weakness, or any reaction that concerns you, and take raltegravir only as prescribed by a licensed medical professional.

Report new or worsening symptoms to your doctor promptly. This is not a complete list — see the patient information leaflet.

Store as directed on the patient information leaflet, usually at room temperature away from moisture and out of reach of children. Always follow the storage guidance supplied with your medicine.

Raltegravir was the first integrase strand transfer inhibitor and remains widely used, though it is now one of several INSTIs alongside molecules such as dolutegravir and bictegravir. These agents share the same broad mechanism of blocking HIV integrase but differ in dosing frequency, tablet count and how they combine with other antiretrovirals. Some newer options are formulated as single-tablet regimens, whereas raltegravir is taken as a separate component. Which integrase inhibitor is appropriate is a clinical decision made by an HIV specialist based on resistance, interactions and individual tolerability, not on cost alone.

Isentress carries a premium brand price because Merck funds the original research, clinical trials, regulatory approval and long-term marketing behind raltegravir. While that brand holds market exclusivity, its pricing reflects those costs. Once other licensed manufacturers are permitted to produce the same molecule, they supply generic raltegravir without repeating that investment, which is the main reason raltegravir cost falls substantially at the generic level. The active ingredient, strength and tablet form are unchanged; what differs is the price. This makes ongoing HIV treatment more affordable while the medicine is used as prescribed by a licensed medical professional.

Raltegravir is a long-term treatment taken every day as part of a combination regimen, so consistent adherence matters for keeping the virus suppressed. Your HIV clinician will typically monitor viral load and CD4 counts through regular blood tests to check how well the regimen is working, and will review side effects and any other medicines you take for interactions. Missed doses can allow the virus to rebound or develop resistance, so it is important to follow the schedule exactly. Any new symptoms, other prescriptions or concerns should be discussed with your specialist rather than stopping treatment.